– USA, MA – Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Stephen Berenson as Chairman of its Board of Directors. Roger Pomerantz, M.D., has decided to step down after serving as Chairman of the Board since 2013. Dr. Pomerantz will continue to serve as an advisor to Seres.
“Seres is the clear leader in the development of microbiome therapeutics and I am honored to chair the Company’s Board. We are nearing an important period for the Company with two late-stage clinical readouts anticipated next year and with continued progress on very promising earlier stage pipeline programs. I look forward to working with the team to create substantial long-term shareholder value developing important new medicines,” said Mr. Berenson, Chairman of Seres’ Board of Directors.
About Stephen Berenson
Mr. Berenson is a managing partner at Flagship Pioneering. Prior to Flagship, Mr. Berenson spent 33 years in various roles as an investment banker at J.P. Morgan. During his last 12 years at J.P. Morgan, Mr. Berenson was Vice Chairman of Investment Banking, where he focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was a co-founder of J.P. Morgan’s Global Strategic Advisory Council and the firm’s Board Initiative. Mr. Berenson also serves on the Board of Directors of Moderna, Inc. and CiBO Technologies, Inc.
“I would like to thank Roger for his important contributions to the Company, both as Chairman and in his earlier role as CEO,” Eric Shaff, President and CEO of Seres commented. “I look forward to continuing to work with Stephen in his expanded role as Chairman. He is a highly accomplished corporate executive who provides invaluable strategic guidance to the Company.”
Mr. Berenson received an S.B. in mathematics from Massachusetts Institute of Technology.
About Seres Therapeutics
Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres’ SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma. SER-301, a next-generation, rationally-designed, live microbiome therapeutic candidate is in preclinical development for ulcerative colitis.
For more information: https://www.serestherapeutics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
